Description
dGpNHpp, a minuscule molecule, is capable of disrupting protein-protein interactions with a specific focus on the nucleotide binding domain (NBD) of CFTR, a protein afflicted with mutation in cystic fibrosis. Its viability as a therapeutic agent lies in its probable ability to rectify the rogue folding and movement patterns of the mutated CFTR protein while opening up new dimensions unconquered until now